Ophthalmic Business News

Novaliq submitted a new drug application to the FDA for CyclASol, a cyclosporine ophthalmic solution for the treatment of dry eye disease signs and symptoms, according to a company press release.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview David F. Chang, MD.

Tarcocimab tedromer was noninferior to aflibercept in change from baseline in best corrected visual acuity in patients with macular edema due to retinal vein occlusion, according to a press release from Kodiak Sciences.

In the ninth part of a 12-part series, Peter J. Polack, MD, FACS, offers insight on his second website conversion tactic.

The first participant has been enrolled in a phase 2a clinical trial investigating TP-03 as a treatment for meibomian gland dysfunction in those with Demodex mites, according to a press release from Tarsus Pharmaceuticals.

The first subject has been dosed in the phase 3 registrational COMET-3 study investigating AR-15512 for the treatment of dry eye disease, according to a press release from Aerie Pharmaceuticals.

The FDA granted 510(k) clearance for the iStent infinite trabecular micro-bypass system to reduce IOP as a stand-alone procedure for uncontrolled primary open-angle glaucoma, according to a press release from Glaukos.

LumiThera has purchased the assets of MacuLogix through its wholly owned subsidiary, according to a press release.

The FDA approved Cimerli as a biosimilar to and interchangeable with Lucentis, according to a press release from Coherus BioSciences.

The first patient has been dosed in the phase 2 DR:EAM clinical trial assessing OTT166 for the treatment of diabetic retinopathy, according to a press release from OcuTerra Therapeutics.